T he human immunodeficiency virus type 1 (HIV-1) is a ∼145-nm lipidenveloped globular lentivirus 1, 2 and is the causative agent of the acquired immunodeficiency syndrome (AIDS). 3 Most, if not all, of the steps in its replication cycle have been studied via ensemble biochemistry and virology, which has resulted in 26 HIV-1 targeting drugs (U.S. Food and Drug Administration) available today. Redundancies in the replication cycle, such as the different possible pathways used by HIV-1 to enter the cell 4 and frequent defects during replication caused by, for example, the low-fidelity reverse transcriptase enzyme, 5 lead to heterogeneity between viral particles which only can be resolved by research methods that allow a single-particle type of analysis. 4À6 Because of the current availability of sensitive single-molecule imaging systems, and their compatibility with complex biological systems, these methods are especially suited for HIV-1 research at the single-virus level. Single-molecule fluorescence microscopy (SMF), in particular, has been fundamental for a better understanding of the viral lifecycle of different viruses, including the HIV-1. 7, 8 For example, the ability to track individual viral particles in real-time with single-molecule sensitivity is a robust tool for characterizing the dynamic interaction between viruses and target cells and for investigating viral infection routes inside cells. 4,7,9À16 Super-resolution fluorescence methods have offered the possibility for visualizing structural features of individual HIV-1 viral particles and for defining the distribution of the viral proteins inside a virus at the nanoscopic scale. 17À20 Lacking in the field of single-virus research, however, are quantitative methods for probing proteinÀ protein interactions (PPIs) at the level of a single viral entity and/or of intracellular viral complexes during the infectious pathway. A clear niche for such methods exists in research on HIV-1 replication, but such methods would also constitute a valuable generic tool for studying other (enveloped) viruses. In the context of inhibitor screening, probing viral PPIs directly in viruses could reduce the overall difficulty and cost associated with setting up high-throughput assays, since protein purification steps, that often hamper in vitro protein investigations, would be eliminated. Finally, unlike lipid vesicle encapsulation, employing a viral targeting strategy would allow PPIs to be expressed in a native cellular environment, rather than having to produce purified protein that might suffer from low stability or solubility. Furthermore, at the nanoscopic virus level, interactions can be probed at concentrations exceeding the limit for complex detection, allowing PPIs with low interaction affinities to be studied.
Here, we have set up a strategy for probing PPIs of one of the three HIV-1 enzymes, integrase (IN), inside single HIV-1 derived virions. In infected cells, IN is the major constituent of the pre-integration complex (PIC), and catalyzes two temporally and spatially separated reactions with the viral cDNA genome as a substrate: (i) the 3 0 -processing reaction in the cytosol, in which a conserved dinucleotide is cleaved from the viral cDNA ends, and (ii) the strand transfer reaction in the nucleus, in which the viral cDNA is inserted into the target host cell chromatin. 21, 22 The enzyme also plays a pivotal role in the replication cycle of HIV-1 by interacting with different cellular cofactors important for nuclear import and chromatin tethering of the virus in infected cells. 23À31 Tightly coupled with its different functions is the oligomerization state of IN. HIV-1 IN consists of three distinct domains, an N-terminal domain (NTD; residues 1À54), a catalytic core domain (CCD; residues 55À209), and a C-terminal domain (CTD; residues 210À288), which all three have been shown to crystallize into a dimer. 32À39 The active and minimal quaternary structure of full-length IN for in vitro 3 0 -processing is a dimer, while at least a tetramer is needed for concerted in vitro strand transfer. 40À44 Because of its very low intrinsic solubility in vitro, structural studies on fulllength HIV-1 IN have been challenging. However, it has been shown that different oligomeric species of IN are present in viruses, 45 a tetrameric IN is present in the INÀDNA complex (alias: the "intasome") of prototype foamy virus (PFV), a distantly related retrovirus, 46 and that an HIV-1 IN tetramer likely consists of two stacked reaching dimers that are stabilized by CCDÀCCD interactions. 47 Finally, the transcriptional coactivator LEDGF/p75 (Lens epitheliumderived growth factor), a cellular cofactor of IN that tethers the latter and the PIC to the host chromatin, is known to specifically stabilize a tetrameric structure of lentiviral IN, 24 Figure 1A ). During viral assembly, Vpr interacts with the p6-motif in the group-specific antigen (Gag), as such passively dragging IN-FP into the virus. Cleavage of the latter from Vpr during the viral maturation finally releases the IN-FP inside the newly synthesized virion. Next, we employ total internal reflection fluorescence microscopy (TIRFM) ( Figure 1B , Supporting Information Figure S1 ) on clean solutions of immobilized fluorescent virions to demonstrate that the IN-FP content of viral particles can be accurately quantified. Finally, we employ Förster resonance energy transfer (FRET) via acceptor photobleaching (AP) to prove, with proper control experiments, that IN oligomerization can be probed at the level of a single virus in vitro and at the level of intracellular viral complexes inside infected cells ( Figure 1C ).
RESULTS AND DISCUSSION
Characterization of HIV IN(D64E)/IN-FP viral Particles. To be able to generate different fluorescent viruses, we first constructed a set of plasmids encoding Vpr-fusions with a fluorescently labeled IN (Vpr-IN-mTFP1, Vpr-INmVenus) or with control proteins (Vpr-IN-mTFP1-Venus, Vpr-mTFP1, Vpr-mVenus). To produce the fluorescent viral particles, we expressed either of these proteins together in 293T cells with viral envelope proteins and with the major protein components of HIV-1: Gag precursor polyprotein, consisting of the structural proteins (Matrix, MA; Capsid, CA; p6 and Nucleocapsid, NC) and the Gag-Pol precursor polyprotein, additionally containing the three viral enzymes (protease, PR; reverse transcriptase, RT; and IN). As an internal control, gagpol-encoded IN was rendered catalytically dead by a D64E mutation. 56 Figure 1A ). To determine whether viral particles containing Vpr-IN-FP can be generated, we performed Western blot analysis on lysates of viral productions with specific antibodies against IN, CA (24 kDa), and RT (51 and 66 kDa). In all conditions tested, RT, untagged IN D64E (32 kDa), and CA were detected as single bands ( Figure 2A , lanes 1À4). Unprocessed (72 kDa) and PRprocessed (60 kDa) labeled IN were furthermore observed in HIV and HIV IN-mTFP1þIN-mVenus lysates (Figure 2A, lanes 3 and 4, respectively) , proving that the Vpr-constructs were both incorporated and processed by PR upon viral maturation. The extra bands, detected in the lysates of HIV and HIV IN-mTFP1þIN-mVenus solutions, correspond to products of internal cleavage within mTFP1 (Supporting Information Figure S2 ), as observed before for other FPs having a similar chromophore.
58,59
Since we wished to employ the fluorescent viruses also for infecting cultured cells, we set out to compare the infectivity of the produced viruses with that of wildtype HIV-1. In the genome of the produced HIV viral particles, a firefly luciferase gene (fLuc) is also encoded as an internal control for infectivity of the viruses. To test this, we challenged cultured cells with different dilutions of the viral particles and evaluated the fLuc activity with a standard assay three days posttransduction. Viral particles containing a catalytically dead IN D64E and no IN-FP (HIV D64E ) exhibited 20-fold lower expression of the fLuc gene compared to wildtype HIV viral particles (HIV WT ), as has been observed before ( Figure 2B ). 60 ARTICLE increase of expression of the fLuc gene, proving the specificity of rescue by fluorescently labeled IN ( Figure 2B ). Noteworthy, the average infectivity is not necessarily representative of the infectivity of the fluorescent viral particle population, since only those viruses in the virus preparation that have an incorporated Vpr-IN-FP will exhibit both a significant infectivity rescue, as well as fluorescence. As a final control experiment, we wished to directly visualize the infectivity of the fluorescent viruses. To that extent, we infected HeLaP4 cells with the fluorescent viruses, stained the cells three hours post-infection with antibodies recognizing the CA protein and performed confocal imaging. To position the intracellular PICs relative to the nucleus, we also immunostained the nuclear lamina (lamin A/C). In cells infected with different viral particles, mTFP1 or mVenus fluorescence was indeed detected ( Figure 2DÀG , green), indicating complexes in the cell that contained the mTFP1 or mVenus protein, respectively. Colocalization ( Figure 2DÀG , yellow) of CA containing complexes ( Figure 2DÀG, 54 Synchronization of infection might provide a more homogeneous phenotype of intracellular complexes.
Taken together, at the ensemble level, Vpr-labeled fluorescent IN is incorporated into viruses, maturates, efficiently trans-complements the catalytically inactive Accurate Control of the Viral Particle Content. To probe PPIs in single viruses at protein concentrations exhibiting significant complex formation but avoiding falsepositive FRET, one needs accurate control of the concentration of active FRET donor and acceptor in the produced viral particles. To show that this can be achieved by Vpr transincorporation, we performed TIRFM experiments on coverslips coated with solutions containing HIV or HIV IN-mVenus at concentrations at which single particles could be discerned. For both samples, brightly fluorescent spots were observed with a diffraction-limited size of ∼200À 300 nm after excitation at 445 nm (mTFP1) or 514 nm (mVenus) ( Figure 3A ). To investigate whether these particles indeed represent HIV-1 virions, we performed a counterstaining with an antibody recognizing the capsid protein (Supporting Information Figure S3 ). From single-particle intensity analyses, we could conclude that the intensity histogram of the HIV IN-mVenus particles containing detectable levels of IN-mVenus completely overlaps with the intensity histogram of the HIV IN-mVenus particles that colocalize with CA, while for HIV particles containing detectable levels of IN-mTFP1, the intensity histogram is slightly lower compared to the intensity histogram of HIV particles that colocalize with CA (Supporting Information Figure S3 ). It is possible that some particles in HIV IN-mTFP1 samples are not immunostained well, or might even constitute VSV-G envelope-induced microvesicles containing only IN-FP, 62, 63 an effect that could be related to a possible less efficient folding and/or maturation of the mTFP1 fluorophore. Additionally, the mTFP1 exhibits a lower brightness under our experimental conditions (see Supporting Information Figure S6 and Figure 4E ), increasing the likelihood of spurious single-particle localization. With respect to misfolding or incomplete maturation, the mEGFP has around an 80% probability of being fluorescent in distinct fusion proteins. 64 For mVenus, a variant of the yellow fluorescent protein (YFP) that contains multiple mutations that accelerate the rate of protein folding and increase maturation at 37°C, we expect this probability to be the same or higher. 53 For mTFP1, unfortunately only little is known about the 
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folding and maturation properties. 52 Determination of the percentage of fluorescent FPs would be useful for more accurate analysis of the number of labeled INs incorporated in the viruses. Nevertheless, these results suggest that experiments of mTFP1-only containing samples need to be interpreted with care. When analyzing FRET experiments, however, only those viral particles that exhibited mVenus (and mTFP1) fluorescence were taken into further analysis, ensuring that the intensity of the particles taken into account likely represent functional virions. As is clear from Figure 3A , intensity variations between particles presumably represent different amounts of internalized IN-FP. To investigate this, we analyzed the dependence of the single-virus intensity on the Vpr-plasmid concentration during production. After localizing 1000À5000 single particles, we determined the single-particle intensity F HIV_IN-FP by 2D Gaussian fitting and plotted the data in a histogram ( Figure 3B ). From the raw data, the average fluorescence intensity per virus, F HIV_IN-FP was calculated ( Figure 3C ). Clearly, the higher the amount of Vpr-INmTFP1/mVenus plasmid used for viral production (from 2.5 to 12.5 μg), the higher the average intensity of the viral particles. To count the number of fluorescent IN-FPs in a single viral particle, we performed a comparative analysis with single FP molecules, obtained by in vitro purification, and immobilized onto the coverslip ( Figure 3B,C) . This way we could deduce that the average intensity of HIV IN-mTFP1 viral particles was between 4 ( 3 and 7.5 ( 7 times higher than that of the single mTFP1 protein, depending on the amount of Vpr-IN-mTFP1 plasmid (2.5À 12.5 μg) used to produce the virus. It needs to be stressed again that these numbers might be biased (see above). For HIV IN-mVenus viral particles, the average number of fluorescing mVenus varied between 3 ( 2.5 and 5.5 ( 5, with increasing amounts of Vpr-IN-mVenus plasmid (2.5À12.5 μg). As a comparison, considering a ∼145-nm viral diameter and 5 incorporated fluorescent IN-FP molecules, this amounts to a concentration of ∼5 nM in the virus. A significant spread (standard deviation σ) on the single-virus FP content is also obvious (error bars in Figure 3C ). This spread, which increased with Vpr-plasmid concentration, arises due to a varying per-cell concentration of Vpr-IN-FP in transiently transfected cells prior to assembly into viral particles. Importantly, a stably and homogeneously expressing Vpr-IN-FP cell line is not possible because of the known cytotoxic properties of Vpr. Figure 2B ). Finally, future studies might be performed with more recently engineered teal-or cyan-FPs, exhibiting superior signalto-noise levels, or even with a more red-shifted FRET pair such as the recently developed mClover-mRuby2. At low 514-nm laser intensity, individual bright viral particles exhibited a moderate decrease in intensity over a time-span of 100 s, while at intermediate and high excitation intensities, the largest proportion of the fluorescent particles photobleached ( Figure 4A ). When illuminated for at least 30 s at 15.4 W/cm 2 , the probability of completely photobleaching virusincorporated mVenus approaches unity, proving that the mVenus is a suitable FRET acceptor probe for the AP method. We performed a similar experiment using 445-nm excitation, to optimize the imaging conditions for HIV IN-mTFP1 viral particles (Supporting Information Figure S5 ). In brief, at 0.45 W/cm 2 mTFP1-bearing viral particles can be imaged, during the 2-s time interval needed to quantify FRET, without significant photobleaching. We also tested the effect of high 514-nm laser intensities on the mTFP1 fluorescence. As can be seen in Figure 4B , the average viral particle intensity before and after illumination was not altered for a sample containing HIV IN-mTFP1 for 30 s with 15.4 W/cm 2 514-nm light, proving the absence of a negative effect of 514 nm illumination on mTFP1, and thus a highly specific excitation of mVenus.
In a next step, we employed viral particles transincorporating a Vpr-IN-mTFP1-Venus fusion construct (HIV IN-mTFP1-Venus ). On coverslips coated with these particles, we imaged mTFP1 at low laser power in the blue detection channel ( Figure 4C , "D,pre") and subsequently imaged mVenus at low laser power in the yellow detection channel ( Figure 4C, "A,pre") . Next, mVenus was photobleached for 30 s at high power and imaged again at low power ( Figure 4C, "A,post") . Finally, mTFP1 was imaged again at low power ( Figure 4C , "D,post"). As can be seen in Figure 4C , after the photobleaching, only background signal was detected for mVenus, while a careful comparison of the mTFP1 images already reveals an increased brightness of the mTFP1 molecules. Next, spots were localized and fitted with a 2D-Gaussian function in the D,pre; D,post; and A,pre fluorescence images, and those particles located within 160 nm (2 pixels) distance in all three images and lacking neighboring particles within 400 nm (5 pixels) were considered to be individual viral particles containing both the fluorescing FRET donor and fluorescing FRET acceptor. From this population (∼5000 viral particles), the per-viral particle FRET ratio, r FRET , was calculated and plotted in a histogram (eq 1). If FRET occurred, the average FRET ratio, r FRET , should be larger than unity. Indeed, relative to the negative control (HIV IN-mTFP1 ) , the HIV IN-mTFP1-Venus sample exhibited a right-shifted (and wider) r FRET distribution (p < 0.01). Histograms were fitted with a Gaussian distribution, with a mean value r FRET for HIV IN-mTFP1-Venus viral particles of 1.87 ( 0.07 ( Figure 4D , solid line). Without photobleaching of the acceptor, the calculated r FRET was 1.06 ( 0.02, indicating that the increase in FRET donor intensity is indeed due to photobleaching of the acceptor (Supporting Information Table S1 ). For the HIV IN-mTFP1 viral particles, where no FRET could occur due to the absence of the acceptor, the r FRET was 1.05 ( 0.06 ( Figure 4D, dashed line) .
Another way to analyze FRET is by plotting the postvs pre-bleaching mTFP1 intensity for individual particles and performing a linear fit ( Figure 4E ). The slope of this fit showed similar r 0 FRET values as in Figure 4D ( Figure 4E , cyan/magenta and Supporting Information Table S1 ). The advantage of representing the data this way is that F mTPF1,post can also be plotted against F Venus,pre for HIV IN-mTFP1-Venus ( Figure 4E, black) . The slope then indicated that, when measured at the same excitation intensity (0.45 W/cm 2 ), the per-particle intensity in the Venus imaging channel is about 8-fold higher than that in the mTFP1 channel. Since we calculated that Venus should theoretically be detected only ∼2.4-fold more efficient than mTFP1 in our ARTICLE microscopic setup (Supporting Information Figure S6 ), we can therefore conclude that the mTFP1 fusion folds and/or maturates less efficiently than Venus in the context of IN-mTFP1-Venus, giving rise to viral particles with, on average, an excess of fluorescent Venus protein. Finally, from the mean squared deviation of the scatter plots in Figure 4E , we could conclude that there is a larger variation on the intensity of mTFP1 in HIV IN-mTFP1-Venus (SD = 2402, plotted in magenta) than on the intensity of mTFP1 in HIV IN-mTFP1 (SD = 141, plotted in cyan), which can partly be explained by a relatively larger effect of Poissonian shot noise induced localization errors in the F mTFP1,pre image of HIV IN-mTFP1-Venus , where per-particle intensities were considerably lower due to mTFP1-quenching by FRET. The additional spread of the black data (SD = 9055; Venus vs mTFP1 in HIV IN-mTFP1-Venus ), on the other hand, is not a FRET related effect, but a direct proof of the variable per-particle concentration ratio of fluorescent Venus vs mTFP1, even when the proteins are expressed as part of the same construct. Finally, we also calculated the apparent FRET efficiency, E, with E = 1 À (F D,pre /F D,post ) ( Figure 4F ). The average E (∼0.44) for HIV IN-mTFP1-Venus was in good agreement with reported values for constructs having a similar distance between the same D and A, but measured with time-domain fluorescence lifetime imaging microscopy (FRET-FLIM). 67 This result shows that we can accurately measure energy transfer with our AP approach in individual viral particles. In summary, on the basis of excitation intensity dependence studies, we conclude that both donor and acceptor probes are suitable for the AP-FRET approach, although we did point out that the mTFP1 likely exhibits suboptimal folding and/or maturation. Additionally, the observation of FRET inside these viral particles provides a basic proof-of-principle that viral particles can be used as nanoscopic test tubes for probing PPIs. Next, we will employ the developed method to investigate actual PPIs inside individual viral particles.
IN Forms Stable Oligomers in Viral Particles. To investigate whether IN oligomers can be detected in HIV-1 viral particles, we produced viral particles containing IN-mTFP1 and IN-mVenus by transfecting the producer cells with the corresponding Vpr-plasmids in a 1:1 stoichiometry, which empirically worked best. For viral particles containing both mTFP1 and mVenus fluorescence (HIV IN-mTFP1þIN-mVenus ) , an r FRET (eq 1) value of 1.27 ( 0.09 was measured, suggesting the presence of IN-IN oligomers capable of FRET ( Figure 5A ,B, solid black line and Supporting Information Table S2 ). To prove that overexpression of the Vpr-plasmids in the producer cells did not result in an aspecific FRET signal, we repeated the experiment for viral particles produced in cells expressing Vpr-FP plasmids instead of Vpr-IN-FP. No increased r FRET was observed in these control viral particles ( Figure 5A ,B, Supporting Information Table S2 ), suggesting that the observed increase in r FRET is due to oligomerization of fluorescently labeled IN.
To investigate IN oligomerization in viral particles in more detail and to be able to corroborate our initial observations, we sought to reduce the dimerization affinity of IN. As shown before in crude lysates, 68 W108
is crucial for IN multimerization ( Figure 5C ). Combined in silico energy calculations on the IN catalytic core domain dimer (PDB ID: 2ITG) and predictions from the Robetta Computational Interface Alanine Scanning Server (http://robetta.bakerlab.org/alascansubmit.jsp), 69 suggest that a W108G substitution can create an energetically unfavorable cavity at the interface, reducing dimerization and higher order oligomerization. The effect of W108G on oligomerization was first investigated with an in vitro AlphaScreen interaction assay ( Figure 5D ) 48 No increase in r FRET could be observed in the presence of Raltegravir or DMSO, while on the contrary, the FRET ratio was significantly larger for viral particles produced in the presence of the ARTICLE CX05045 LEDGIN. 48 Here, we now corroborated this finding and additionally show that an increase in FRET also occurs in the presence of the CX14442 LEDGIN. This strongly suggests IN oligomerization enhancement is indeed a general mechanism of LEDGINs, and not a unique property of the CX05045 compound ( Figure 5F ).
In summary, these experiments allowed us to prove, directly inside HIV-1 derived virions, that IN is part of an oligomer, and corroborate previously performed in vitro experiments involving cross-linking, lysis, and Western blotting of whole-population preparations. 45, 71 Our findings involving a particular set of IN-mTFP1þIN-mVenus ) and used these dual-color viral particles to infect HeLaP4 cells. Three hours post-infection, cells were immunostained with antibodies recognizing the epidermal growth factor receptor (EGFR), which are present on the cell surface, as well as with antibodies recognizing the nuclear lamina to delineate the cell/nucleus boundaries ( Figure 6A ). After localizing and fitting the viral complexes (∼50À500) in the cytoplasm of the cells, we calculated an r FRET value of 1.30 ( 0.09 for dual color viral particles containing both mTFP1 and mVenus fluorescence ( Figure 6B ,C and Supporting Information Table S3 ). We also produced viral particles in cells expressing Vpr-FP instead of Vpr-IN-FP and used these particles to infect HeLaP4 cells (∼50À200). In agreement with the results obtained from viral particles in solution, no increased r FRET was observed, proving the specificity of the observed FRET (Supporting Information Table S3 ). Logically, considerably less dual-color viral complexes were observed in cells infected Taken together, these experiments proved that PPIs can be studied inside cells in the context of a viral complex, and more specifically, that IN also takes part in and stays part of an oligomeric complex.
In conclusion of this work, we have developed, characterized, and applied an experimental methodology for assessing PPIs of IN via single-molecule FRET inside infection-competent HIV-1 derived viral particles. With our methodology, we visualized IN oligomerization directly inside HIV-1 virions and for the first time provided direct experimental proof for the persistence of IN oligomers inside complexes within HIV-1 infected cells. We observed a similar FRET ratio in solution and in cells, suggesting that already in the mature virion, the IN is stably associated as an oligomeric complex with the viral content that eventually forms the PIC. Future studies might provide an even more detailed insight into the function of IN oligomers throughout viral replication, and the involvement of human cofactors in this. FRET measurements inside cells might also be combined with single-particle tracking image correlation for following the fate of individual viral complexes, 73 fluorescence lifetime imaging for more robust FRET quantifications, 74 or advanced multicolor fluctuation microscopy for monitoring multiple interactions simultaneously. 75, 76 More generally, our work should serve as an experimental proof that PPIs can be quantitatively studied, by TIRFM and acceptor photobleaching mediated FRET with fluorescent proteins as fluorescent markers, at the level of single viruses. Therefore, we feel our strategy has the potential for being widely applicable for studying other PPIs of HIV, but potentially also PPIs of other viruses, in the miniaturized context of a single viral entity in solution, but also in infected cells.
MATERIAL AND METHODS
Plasmids. The HIV-1 molecular clone pNL4-3.Luc.R ARTICLE the following primer 5 0 -TGGCCGGCCGCGGGCCCGTG. The original template was digested with DpnI, and the complementary strand was synthesized using the GFP_Nr primer.
In Vitro Purification of Fluorescent Proteins. For protein purification, pRSET-Venus and -mTFP1 were transformed into JM109-(DE3) Escherichia coli cells (Promega, Leiden, The Netherlands), and a single colony was picked to inoculate 350 mL of LB medium supplemented with ampicillin (100 mg/L in 50% ethanol, Carl Roth GmbH, Karlsruhe, Germany). The culture was incubated at 20°C for 48À72 h. The bacterial cells were harvested, resuspended in phosphate buffered saline (PBS, Sigma-Aldrich, Bornem, Belgium) containing protease inhibitor (cOmplete Mini, 1/50 dilutions, Roche Diagnostics GmbH, Mannheim, Germany), and lysed using a French press (SIMAminco, Spectronic Instruments, Inc., Leeds, U.K.). The proteins were purified using metal affinity beads, Ni-NTA (Ni 2þ nitrilotriacetic acid) agarose resin (Qiagen, Venlo, The Netherlands). Elution of the protein was done using Tris/NaCl (100 mM/ 300 mM, pH 7.2) supplemented with 200 mM imidazole (Sigma-Aldrich, pH 7.4), followed by buffer exchange on a PD-10 desalting column (GE Healtcare, Londen, U.K.). Elution was performed with Tris/NaCl (50 mM/150 mM).
Eukaryotic Cell Culture. HEK293T cells and HeLaP4 cells were maintained at 37°C in a 5% CO 2 humidified atmosphere in Dulbecco's modified Eagle medium (Life Technologies Europe, Merelbeke, Belgium) supplemented with 8% (v/v) fetal bovine serum (FBS, Life Technologies) and 50 μg/mL gentamicin (Life Technologies).
Virus Production. Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped HIV-1 derived viral particles containing fluorescent IN were generated by a Vpr-mediated transincorporation strategy. 54, 55, 61 For the in vitro single-virus experiments, 7 Â 10 5 HEK293T producer cells were seeded per well in a 6-well plate in DMEM supplemented with 2% FBS. At a cell density of 90%, cells were transfected with 1.25 μg of VSV-G, 3.75 μg of pD64E, and 1.25 μg of each Vpr plasmid per well using branched polyethylenimine (bPEI, 25 μL, 10 μM, Sigma-Aldrich). Six hours post-transfection, the medium was replaced with pre-warmed OptiMEM (Life Technologies) supplemented with 50 μg/mL gentamicin. At 48 h post-transfection, the cell supernatant was filtered through a 0.45-μm pore-size syringe filter (Sartorius, Vilvoorde, Belgium). These supernatants then were either used directly for microscopy experiments or stored at À80°C until use. For the plasmid titration experiments and all other experiments, 6 Â 10 6 293T cells were plated in a 10 cm petridish in DMEM (2% FBS, gentamicin). After overnight incubation, cells were transfected with a transfection mix (1400 μL total volume in OptiMEM) containing 100 μL of 10 μM bPEI, 15 μg of pD64E, 5 μg of pVSV-G, and 10 μg of Vpr-(IN)-FP. Six hours post-transfection, the transfection medium was replaced with fresh OptiMEM (50 μg/mL gentamicin). Supernatants were collected 48 h post-transfection, filtered through a 0.45-μm filter (Sartorius), and concentrated by ultracentrifugation sedimentation on a 60% (w/v) iodixanol cushion (141 000g, 90 min, SW28 rotor, Beckman Coulter, Ireland). Next, the iodixanol was removed by ultrafiltration (Vivaspin, NMWL = 50K, Sartorius). For the coimmunoprecipitation, the ultrafiltrate was recovered in 150 mM NaCl, for all other experiments in OptiMEM. For the production of viruses in presence of inhibitors, the transfection medium was replaced with gentamicin supplemented OptiMEM with Raltegravir (0.03 μM), CX05045 (5 μM), or CX14442 (0.3 μM).
Western Blotting and Coimmunoprecipitation. Protein concentrations of supernatants from virus-producing cells were first determined using a bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Geel, Belgium) after addition of 1% (w/v) SDS (Sigma-Aldrich).
For the Western blotting, 20 μg of protein was directly loaded onto a 12% (w/v) sodiumdodecyl sulfate polyacrylamide gelelectrophoresis (SDS-PAGE, Life Technologies) gel and electroblotted onto polyvinylidene difluoride membranes (PVDF, Bio-Rad laboratories, Nazareth Eke, Belgium). For the coimmunoprecipitation experiments, 70 μg of protein in 150 mM NaCl was lysed with an equal amount of 2Â lysis buffer [1 M Tris/HCl pH 7.5, 300 mM NaCl, 20% (v/v) glycerol, 1 mM MgCl 2 , 1% (v/v) Triton X-100, 4 mM dithiothreitol (DTT), cOmplete protease inhibitors (1/50 dilutions, Roche)]. Five micrograms of protein was diluted directly into SDS-PAGE loading buffer (200 mM Tris-HCl pH 6.8, 400 mM DTT, 8% (w/v) SDS, 40% (v/v) glycerol, 0.5% bromophenol blue). Viral lysates were incubated with anti-GFP antibody (in house) for 4 h, followed by 3 h incubation with 40 μL of protein G-agarose beads (Roche Molecular Biochemicals). After this, the agarose beads were washed 5 times with a 1Â lysis buffer containing 300 mM NaCl, and the immunoprecipitated proteins were eluted in 30 μL of SDS-PAGE loading buffer. The crude lysates (as loading control) and immunoprecipitates were loaded onto a protein gel (4À12% NuPAGE Novex Bis-Tris Gel, Life Technologies) and electroblotted onto a PVDF membrane (Bio-Rad). Next, the same anti-IN as for normal Western blotting was used for primary staining, and a horseradish peroxidase-conjugated rabbit antimouse antibody (Dako) for secondary staining. Detection was by chemiluminescence (ECL þ , Amersham Bioscience). Single-Cycle Viral Infectivity Assay. For testing viral infectivity, 2 Â 10 4 HeLaP4 cells were seeded per well in a 96-well plate and infected the next day with a volume (equivalent to 500 ng of p24 antigen) of filtered supernatant from virus-producing cells. At 72 h post-infection, cells were lysed and luciferase activity was measured using fLuc assay reagent (Promega GMBH, Mannheim, Germany). Each virus sample was tested in triplicate with a serial 3-fold dilution of virus. Data are presented as relative infectivity compared to viral particles lacking Vprincorporation.
Immunofluorescence Imaging. Visualization of cells transduced with viral particles was performed with a laser scanning microscope (Fluoview FV1000, Olympus, Tokyo, Japan). The objective and the excitation polychroic mirror used were UPLSAPO 60Â NA1.2 W and DM405-458/515/559/635, respectively (Olympus). 3D confocal stacks of fixed cells were acquired using a Z-step size of 0.3 μm. A 440-nm diode laser was used for exciting mTFP1 and a 514-nm diode laser for mVenus. Emission light was collected at 455À500 and 505À540 nm, respectively. Alexa Fluor 555 was excited using a 559-nm diode laser, and Alexa Fluor 647 was excited using a 635-nm diode laser. Emission light was collected at 575À620 and 655À755 nm, respectively. In absence of mTFP1 and/or mVenus, no fluorescence was observed when exciting with 440 or 514 nm. The image resolution was 512 Â 512 pixels, with a pixel size of 160 nm. For the dual or three-color images, different channels were combined for each Z-plane and three consecutive Z-planes were then assembled using ImageJ software (NIH).
TIRF Microscopy in Vitro. For fluorescence imaging of the viral particles, virus-containing cell supernatants were diluted and ARTICLE immobilized in 0.1% (w/v) poly-D-lysine (Sigma-Aldrich) coated wells in a #1 Lab-Tek chambered coverglass (VWR international, Leuven, Belgium) for 4 h at 37°C, washed with PBS buffer (Life Technologies), fixed with 4% (v/v) paraformaldehyde (SigmaAldrich) in PBS, washed twice with PBS, and kept at room temperature in PBS. Imaging was subsequently performed on an inverted microscope (Olympus IX-71, Olympus NV, Aartselaar, Belgium) by objective-type total internal reflection (TIR) excitation and wide field detection. The mTFP1 was excited at 445 nm (Cube 445-40c, Coherent, Utrecht, The Netherlands) and mVenus at 514 nm (Sapphire 514-100 CW CDRH, 100 mW, Coherent) (Supporting Information Figure S1 ). The two different laser lines were combined using a dichroic mirror (z488rdc, Chroma Technology GmbH, Olching, Germany), circularly polarized (WPQ05M-532, Thorlabs GmbH, Munich, Germany) and expanded 50 times to achieve a homogenized beam profile in the part of the sample that is imaged on the electron multiplying charge coupled device (EMCCD) chip and passed through a ∼1-cm iris to limit the illuminated area in the sample, before finally being focused on the back focal plane of the objective (PlanApo 60Â, NA1.45 oil TIRFM, Olympus) through a 500-mm planoconvex achromatic lens (KPX211-C BK7 Precision Plano-Convex lens, Newport). Emission was collected by the same objective and split by a polychroic mirror (z445/514/633 RPC, Chroma) into a blue emission channel for mTFP1 detection (HQ485/40m, Chroma) and a yellow emission channel for mVenus detection (Razor Edge Long Pass 514 filter, Semrock, Rochester, NY). The fluorescence image was expanded 3.3-fold (PE eyepiece 125, 3.3Â, Olympus) and focused onto an electron multiplying charged coupled device (EM-CCD) (ImagEM, Hamamatsu, Louvain-La-Neuve, Belgium). The image size was 40 Â 40 μm 2 and image resolution was 512 Â 512 pixels. Images were acquired as the average of 20 consecutive 100 ms integration time frames, and the EM-gain was set on 190.
TIRF Microscopy in Cells. The intracellular measurements were performed on an inverted microscope (Olympus IX-83, Olympus NV) equipped with a TIRF oil objective as described for the single virus measurements. Alexa Fluor 647 was imaged at 644 nm (Excelsior, Newport Spectra Physisc BV, Utrecht, The Netherlands). This laser line was combined with previous laser lines using a dichroic mirror (z532rdc, Chroma Technology GmbH). Emission was collected by the same objective and split by a 650 long pass dichroic mirror (z650rdc, Chroma Technology GmbH) into a red emission channel for Alexa Fluor 647 detection. Additional filters were used to remove excitation light and signal from other channels, and a 655 long pass filter for Alexa Fluor 647 (HQ665LP, Chroma Technology GmbH).
Data Analysis. Single viral particles were localized on the coverslip by dual-color 2D Gaussian localization of the subdiffraction viral particles (100À150 nm). Subsequently, the single particle integrated fluorescence intensity per virus of the FRET donor before (F D,pre ) vs after (F D,post ) photobleaching and of the FRET acceptor was extracted. Single-molecule localization/ fitting was performed with Localizer. 79 FRET was finally quantified by calculating the FRET ratio:
where F D,pre and F D,post are the pre-and post-bleaching intensities of the FRET donor after donor excitation, respectively. 80 If FRET occurred between donor and acceptor, an increase of the donor fluorescence is observed upon photobleaching of the acceptor. Typically, data was collected from 20 to 50 different positions in a well, which corresponds to an average of ∼1000À5000 viral particles per measurement. The per-virus r FRET values were binned into a histogram that was fitted with a Gaussian distribution (OriginPro 8, OriginLab, Northampton, MA). The average of the Gauss function was taken as the average r FRET and the σ as the standard deviation. Singlemolecule photobleaching curves were obtained using an inhouse written routine in the Matlab programming language (The MathWorks, Eindhoven, The Netherlands). Statistical analyses were performed with a Student's t test with unequal variance with p < 0.01 as the criterion of significance. AlphaScreen ProteinÀProtein Interaction Assay. AlphaScreen (PerkinElmer, Zaventem, Belgium) is a proximity based chemiluminescence assay that allows studying bimolecular interactions in vitro. The assay was performed largely as described before. 81 In brief, glutathione S-transferase (GST) tagged HIV-1 IN was purified as described previously. 81 Wild-type IN-His 6 and the point mutant IN W108G -His 6 were purified as described previously. 26 The assay buffer was 25 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM DTT, 1 mM MgCl 2 0.1% (w/v) BSA, and 0.1% (v/v) Tween-20. Per well in a 384-well microtiter plate (OptiPlate, PerkinElmer), 5 μL of buffer, 5 μL of 5Â working solutions of GST-IN, and IN-His 6 or IN W108G -His 6 were added. The plate was sealed and left to incubate for 3 h at 4°C. Next, 10 μL of a mix of glutathione donor beads and Ni 2þ -chelate acceptor beads was added, bringing the final volume to 25 μL and establishing final concentrations of 20 μg/mL for the beads, 15 nM for GST-IN and 0À150 nM for IN-His 6 or IN W108G -His 6 . The plate was sealed again and incubated for and additional 2 h at room temperature. The AlphaScreen signal (520À620 nm) was acquired with a plate reader (EnVision Multilabel, PerkinElmer) and data were analyzed using Prism 5.0 (GraphPad Software, La Jolla, CA).
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